Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PAVmed (PAVM) Change in Receivables (2022 - 2025)

PAVmed has reported Change in Receivables over the past 4 years, most recently at $12000.0 for Q4 2025.

  • For Q4 2025, Change in Receivables rose 500.0% year-over-year to $12000.0; the TTM value through Dec 2025 reached -$3000.0, down 101.61%, while the annual FY2025 figure was -$3000.0, 93.02% up from the prior year.
  • Change in Receivables for Q4 2025 was $12000.0 at PAVmed, up from -$7000.0 in the prior quarter.
  • Over five years, Change in Receivables peaked at $152000.0 in Q2 2024 and troughed at -$111000.0 in Q1 2022.
  • A 4-year average of $1285.7 and a median of $4000.0 in 2024 define the central range for Change in Receivables.
  • Biggest five-year swings in Change in Receivables: skyrocketed 985.71% in 2024 and later crashed 233.33% in 2025.
  • Year by year, Change in Receivables stood at -$14000.0 in 2022, then skyrocketed by 285.71% to $26000.0 in 2023, then plummeted by 92.31% to $2000.0 in 2024, then soared by 500.0% to $12000.0 in 2025.
  • Business Quant data shows Change in Receivables for PAVM at $12000.0 in Q4 2025, -$7000.0 in Q2 2025, and -$8000.0 in Q1 2025.